What is the comprehensive description of preeclampsia, including its general condition, underlying pathophysiology, typical demographics, major signs and symptoms, early and late assessment findings for US paramedics, emergency medical services management and medication protocols (acute and chronic medications with indications, contraindications, pharmacokinetics and pharmacodynamics), and the complications that can arise if treatment is delayed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Preeclampsia: Comprehensive Overview for US Paramedics

General Condition and Definition

Preeclampsia is a multisystem hypertensive disorder of pregnancy occurring after 20 weeks gestation, characterized by new-onset hypertension (≥140/90 mmHg) and evidence of end-organ damage—proteinuria is no longer required for diagnosis 1. This condition affects 2-5% of pregnancies and represents a medical emergency requiring immediate recognition and transport 2, 3.

The disease results from abnormal placentation and maternal endothelial dysfunction, creating a systemic inflammatory response that affects multiple organ systems 1, 4.

Pathophysiological Changes

Primary Mechanism

  • Abnormal placental development: Trophoblasts fail to properly invade and remodel maternal spiral arteries, leading to placental ischemia and oxidative stress 1
  • Antiangiogenic imbalance: The placenta releases excessive soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng), which antagonize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) 1, 4
  • Endothelial dysfunction: Widespread vasoconstriction and reduced blood flow to vital organs (brain, kidneys, liver, heart) 1

Organ System Effects

  • Cardiovascular: Generalized vasoconstriction, increased systemic vascular resistance, reduced plasma volume
  • Renal: Glomerular endotheliosis (swelling of endothelial cells), proteinuria, decreased GFR, elevated creatinine
  • Hepatic: Periportal necrosis, subcapsular hematoma formation, elevated liver enzymes
  • Hematologic: Thrombocytopenia, hemolysis, DIC in severe cases
  • Neurologic: Cerebral edema, posterior reversible encephalopathy syndrome (PRES), increased seizure risk
  • Placental: Reduced perfusion leading to fetal growth restriction, placental abruption risk

Demographics and Risk Factors

High-Risk Demographics

  • First pregnancy (nulliparity): Most common presentation
  • Age extremes: <20 years or >35 years (especially >40)
  • Multiple gestation: Twins, triplets
  • Obesity: BMI >30
  • Race: Higher incidence and severity in Black women
  • Socioeconomic factors: Limited prenatal care access

Pertinent Medical History

  • Previous preeclampsia: 15-20% recurrence risk
  • Chronic hypertension: 3-4 fold increased risk
  • Diabetes mellitus (pregestational or gestational)
  • Chronic kidney disease: Shares overlapping features with preeclampsia
  • Autoimmune disorders: Systemic lupus erythematosus, antiphospholipid syndrome
  • Family history: First-degree relative with preeclampsia
  • Sleep-disordered breathing: Nearly 2-fold increased risk 5

Why these align: These conditions predispose to endothelial dysfunction, chronic inflammation, and metabolic abnormalities—the same pathways involved in preeclampsia pathogenesis 1.

Major Signs and Symptoms

Classic Presentation

  • Severe headache: Unrelieved by acetaminophen, often frontal or occipital
  • Visual disturbances: Scotomata (blind spots), photophobia, blurred vision, temporary blindness
  • Right upper quadrant or epigastric pain: Indicates hepatic capsule distension or subcapsular hematoma
  • Nausea and vomiting: Especially with severe features
  • Shortness of breath: May indicate pulmonary edema
  • Altered mental status: Confusion, hyperreflexia, clonus

Physical Findings

  • Hypertension: ≥140/90 mmHg (severe: ≥160/110 mmHg)
  • Edema: Particularly facial and hand edema (though non-specific)
  • Hyperreflexia with clonus: Indicates CNS irritability, seizure precursor
  • Decreased urine output: <500 mL/24 hours

Paramedic Assessment Findings

Early Preeclampsia (Without Severe Features)

  • Vital signs: BP 140-159/90-109 mmHg, normal heart rate, normal respiratory rate
  • Mental status: Alert and oriented
  • Complaints: Mild headache, minimal edema, vague discomfort
  • Physical exam: Mild peripheral edema, normal reflexes
  • Fetal movement: Patient reports normal activity (if >28 weeks)

Late/Severe Preeclampsia

  • Vital signs:
    • BP ≥160/110 mmHg (sustained over 15 minutes)
    • Tachycardia (compensatory or distress)
    • Tachypnea (pulmonary edema)
    • Oxygen saturation may be decreased
  • Mental status: Confusion, agitation, decreased GCS
  • Neurologic: Hyperreflexia (3-4+), sustained clonus (≥3 beats), severe unrelenting headache
  • Visual: Scotomata, photophobia, diplopia
  • Respiratory: Crackles on auscultation (pulmonary edema), dyspnea
  • Abdominal: Severe RUQ/epigastric tenderness
  • Skin: Petechiae or ecchymosis (thrombocytopenia/DIC)

Differentiation from Symptoms

Assessment findings are objective measurements and observations (BP, reflexes, lung sounds, mental status), while signs and symptoms include both objective findings and subjective patient complaints (headache, visual changes, pain). Paramedics document both but prioritize objective findings for severity determination.

EMS Management and Treatment Protocol

Initial Scene Assessment and Contact

  1. Scene safety: Standard precautions
  2. Initial impression: Gestational age (>20 weeks?), obvious distress, seizure activity
  3. Primary survey (ABCs):
    • Airway: Assess patency, position for optimal airway if altered mental status
    • Breathing: Rate, depth, lung sounds (pulmonary edema?), oxygen saturation
    • Circulation: Radial pulse quality, skin signs, capillary refill

Focused Assessment (First 2-3 Minutes)

  • Vital signs: BP both arms (use correct cuff size), HR, RR, SpO2, temperature
  • SAMPLE history:
    • S: Headache, visual changes, RUQ pain, dyspnea, decreased fetal movement
    • A: Medication allergies
    • M: Prenatal vitamins, antihypertensives (labetalol, nifedipine, methyldopa), aspirin
    • P: Gestational age, previous pregnancies/outcomes, chronic hypertension, diabetes, kidney disease, previous preeclampsia
    • L: Last meal (aspiration risk if seizure)
    • E: Onset of symptoms, prenatal care compliance
  • Neurologic exam: GCS, pupil response, deep tendon reflexes (patellar), clonus test (dorsiflex foot rapidly)
  • Obstetric assessment: Fundal height, contractions, vaginal bleeding, rupture of membranes, fetal movement

Critical Decision Point: Transport vs. On-Scene Treatment

ALWAYS TRANSPORT IMMEDIATELY for:

  • BP ≥160/110 mmHg
  • Severe headache with visual changes
  • Altered mental status (GCS <15)
  • Seizure activity (eclampsia)
  • RUQ/epigastric pain
  • Pulmonary edema
  • Any signs of severe preeclampsia

No scenario justifies non-transport—preeclampsia is a progressive disease requiring hospital-level care and potential delivery.

On-Scene Management (Minimize Scene Time <10 Minutes)

Positioning

  • Left lateral tilt (15-30 degrees) or full left lateral recumbent to optimize venous return and placental perfusion
  • Elevate head 30 degrees if respiratory distress

Oxygen Therapy

  • Target SpO2 ≥95%
  • Nasal cannula 2-4 L/min or non-rebreather 15 L/min if hypoxic

IV Access

  • Two large-bore IVs (18-gauge or larger) in severe preeclampsia
  • Normal saline at KVO rate (avoid fluid overload—these patients are at risk for pulmonary edema)
  • Do NOT give fluid boluses unless hypotensive from hemorrhage

Seizure Precautions

  • Dim lights, minimize stimulation
  • Suction and airway equipment immediately available
  • Position for airway protection

Medication Management

Magnesium Sulfate (First-Line Seizure Prophylaxis)

Indications:

  • Severe preeclampsia (BP ≥160/110 mmHg)
  • Preeclampsia with severe features (headache, visual changes, RUQ pain, hyperreflexia with clonus)
  • Eclampsia (active seizures)

Contraindications:

  • Myasthenia gravis (relative)
  • Renal failure (relative—requires dose adjustment)

Dosing:

  • Loading dose: 4-6 grams IV over 15-20 minutes (dilute in 100 mL NS)
  • Maintenance: 1-2 grams/hour continuous infusion (if transport >30 minutes and protocols allow)
  • Eclampsia: 4-6 grams IV push over 5 minutes if active seizure

Pharmacokinetics:

  • Onset: Immediate IV
  • Peak: 15 minutes
  • Duration: 30 minutes after bolus
  • Excretion: Renal (100%)

Pharmacodynamics:

  • CNS depression via NMDA receptor antagonism
  • Decreases acetylcholine release at neuromuscular junction
  • Cerebral vasodilation
  • Raises seizure threshold

Monitoring:

  • Respiratory rate (hold if <12/min)
  • Deep tendon reflexes (hold if absent)
  • Urine output (hold if <30 mL/hour—not applicable in field)
  • Therapeutic level: 4-8 mEq/L

Toxicity signs: Absent reflexes (8-10 mEq/L), respiratory depression (10-12 mEq/L), cardiac arrest (>15 mEq/L)

Antidote: Calcium gluconate 1 gram (10 mL of 10% solution) IV over 3 minutes

Antihypertensive Medications

Labetalol (First-Line)

Indications: Severe hypertension (≥160/110 mmHg sustained >15 minutes)

Contraindications:

  • Asthma/reactive airway disease
  • Heart failure
  • Heart block (2nd/3rd degree)
  • Bradycardia (<60 bpm)

Dosing:

  • 10-20 mg IV push over 2 minutes
  • Repeat 20-40 mg every 10 minutes (max 300 mg total)
  • Alternative: 20 mg initial, then 40 mg, then 80 mg every 10 minutes

Pharmacokinetics:

  • Onset: 2-5 minutes IV
  • Peak: 5-15 minutes
  • Duration: 2-4 hours
  • Half-life: 5-8 hours
  • Metabolism: Hepatic

Pharmacodynamics:

  • Combined alpha-1 and non-selective beta-blocker (1:7 ratio)
  • Decreases systemic vascular resistance without reflex tachycardia
  • Maintains uteroplacental blood flow

Target: Reduce BP to 140-150/90-100 mmHg (NOT normotensive—risk of placental hypoperfusion)

Hydralazine (Alternative)

Indications: Severe hypertension when labetalol contraindicated

Contraindications:

  • Coronary artery disease
  • Mitral valve rheumatic heart disease
  • Tachycardia

Dosing:

  • 5-10 mg IV push over 2 minutes
  • Repeat 5-10 mg every 20 minutes (max 30 mg)

Pharmacokinetics:

  • Onset: 10-20 minutes IV
  • Peak: 20-40 minutes
  • Duration: 2-6 hours
  • Metabolism: Hepatic acetylation

Pharmacodynamics:

  • Direct arterial vasodilator
  • Decreases systemic vascular resistance
  • May cause reflex tachycardia and increased cardiac output

Nifedipine (Oral Alternative—If IV Access Difficult)

Indications: Severe hypertension, no IV access

Contraindications: Concurrent magnesium sulfate (relative—may cause profound hypotension)

Dosing:

  • 10 mg immediate-release PO
  • Repeat 10-20 mg every 20 minutes (max 50 mg)

Pharmacokinetics:

  • Onset: 10-20 minutes PO
  • Peak: 30-60 minutes
  • Duration: 4-6 hours
  • Metabolism: Hepatic CYP3A4

Pharmacodynamics:

  • Calcium channel blocker (dihydropyridine)
  • Arterial vasodilation
  • Minimal effect on cardiac contractility

Transport Management

Continuous Monitoring

  • Vital signs every 5 minutes in severe preeclampsia
  • Continuous cardiac monitoring
  • Pulse oximetry
  • Fetal heart tones if equipment available (normal 110-160 bpm)

Communication

  • Early hospital notification: "Preeclampsia with severe features" or "Eclampsia"
  • Report: Age, gestational age, BP, symptoms, medications given, ETA
  • Request OB team activation

Positioning During Transport

  • Maintain left lateral tilt
  • Secure patient to prevent falls during seizure
  • Keep head elevated if respiratory compromise

Seizure Management (Eclampsia)

If seizure occurs:

  1. Protect airway: Position on left side, suction available
  2. Magnesium sulfate: 4-6 grams IV over 5 minutes if not already given
  3. Oxygen: High-flow to maintain SpO2 >95%
  4. Benzodiazepines (if magnesium fails): Lorazepam 2-4 mg IV or midazolam 5-10 mg IM
  5. Do NOT restrain actively seizing patient
  6. Post-ictal: Reassess airway, breathing, circulation

Fluid Management

  • Maintain IV at KVO (30 mL/hour)
  • Avoid fluid boluses unless hemorrhagic shock
  • Total fluids <80 mL/hour (pulmonary edema risk)

Chronic Medications (Preexisting Conditions)

Preeclampsia is NOT a Chronic Condition

Preeclampsia is an acute pregnancy complication that resolves after delivery. However, patients may be on chronic medications for risk factors that predispose to preeclampsia:

Chronic Hypertension Medications

Labetalol

  • Indication: Chronic hypertension in pregnancy
  • Dose: 100-400 mg PO BID-TID
  • Mechanism: Alpha-1 and beta-blocker
  • Why prescribed: Safe in pregnancy, maintains placental perfusion

Nifedipine Extended-Release

  • Indication: Chronic hypertension in pregnancy
  • Dose: 30-90 mg PO daily
  • Mechanism: Calcium channel blocker
  • Why prescribed: Effective, safe in pregnancy

Methyldopa

  • Indication: Chronic hypertension in pregnancy
  • Dose: 250-500 mg PO BID-TID
  • Mechanism: Central alpha-2 agonist
  • Why prescribed: Longest safety record in pregnancy

Contraindicated antihypertensives in pregnancy:

  • ACE inhibitors (enalapril, lisinopril): Fetal renal dysgenesis
  • ARBs (losartan, valsartan): Fetal renal failure
  • Atenolol: Fetal growth restriction

Aspirin (Preventive)

  • Indication: High-risk patients for preeclampsia prevention
  • Dose: 81-162 mg PO daily
  • Timing: Started before 16 weeks, continued until 36 weeks 6
  • Mechanism: Irreversible COX-1 inhibition, antiplatelet effect
  • Pharmacokinetics:
    • Onset: 1 hour
    • Peak: 2 hours
    • Duration: 7-10 days (platelet lifespan)
    • Metabolism: Hepatic to salicylic acid
  • Pharmacodynamics: Inhibits thromboxane A2 synthesis, shifts prostacyclin/thromboxane balance toward vasodilation
  • Why prescribed: Reduces early-onset preeclampsia risk by 50-60% in high-risk women 6, 7

Diabetes Medications

  • Insulin: Multiple formulations (rapid, intermediate, long-acting)
  • Metformin: Sometimes continued in pregnancy
  • Mechanism: Glucose control reduces endothelial dysfunction

Thyroid Medications

  • Levothyroxine: Hypothyroidism increases preeclampsia risk

Complications of Untreated/Delayed Treatment

Immediate Life-Threatening Complications

Eclampsia (Seizures)

  • Mechanism: Cerebral edema, vasospasm, posterior reversible encephalopathy syndrome (PRES)
  • Mortality: 1-2% maternal, 10-15% fetal
  • Sequelae: Aspiration pneumonia, hypoxic brain injury, status epilepticus

HELLP Syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets)

  • Mechanism: Microangiopathic hemolytic anemia, hepatocellular necrosis, platelet consumption
  • Presentation: RUQ pain, nausea/vomiting, malaise
  • Complications: Hepatic rupture (1-2%), DIC, acute renal failure
  • Mortality: 1-3% maternal, 10-60% perinatal

Cerebrovascular Accident (Stroke)

  • Mechanism: Severe hypertension causing hemorrhagic stroke or cerebral infarction
  • Incidence: Leading cause of maternal death in preeclampsia
  • Types: Intracerebral hemorrhage (most common), ischemic stroke, cerebral venous thrombosis

Pulmonary Edema

  • Mechanism: Increased capillary permeability, decreased oncotic pressure, iatrogenic fluid overload
  • Presentation: Dyspnea, crackles, hypoxia, pink frothy sputum
  • Management: Oxygen, diuretics (hospital), avoid fluids

Acute Kidney Injury

  • Mechanism: Glomerular endotheliosis, acute tubular necrosis, cortical necrosis
  • Presentation: Oliguria (<500 mL/24h), elevated creatinine (>1.1 mg/dL)
  • Progression: May require dialysis, permanent renal damage

Placental Abruption

  • Mechanism: Hypertension causes decidual vessel rupture and placental separation
  • Presentation: Vaginal bleeding, abdominal pain, rigid "board-like" uterus, fetal distress
  • Complications: Hemorrhagic shock, DIC, fetal death
  • Incidence: 1-4% in severe preeclampsia (10x normal)

Disseminated Intravascular Coagulation (DIC)

  • Mechanism: Widespread endothelial damage triggers coagulation cascade, consumes clotting factors
  • Presentation: Bleeding from multiple sites, petechiae, ecchymosis
  • Laboratory: Prolonged PT/PTT, low fibrinogen, elevated D-dimer
  • Mortality: 20-30% if untreated

Fetal/Neonatal Complications

Fetal Growth Restriction

  • Mechanism: Placental insufficiency from abnormal spiral artery remodeling
  • Long-term: Increased cardiovascular disease risk in offspring 5

Preterm Birth

  • Iatrogenic: Delivery required for maternal stabilization
  • Spontaneous: Placental dysfunction triggers labor
  • Complications: Respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis

Fetal Demise

  • Mechanism: Severe placental insufficiency, abruption, maternal complications
  • Incidence: 1-2% in severe preeclampsia

Long-Term Maternal Complications

Cardiovascular Disease

  • Risk: 75% increased cardiovascular mortality 5
  • Conditions: Chronic hypertension (RR 3.70), ischemic heart disease (RR 2.16), stroke (RR 1.81) 1
  • Mechanism: Preeclampsia unmasks underlying endothelial dysfunction and metabolic syndrome

Chronic Kidney Disease

  • Risk: 2-3 fold increased
  • Mechanism: Persistent glomerular damage

Psychological Sequelae

  • Depression: 15% of women post-preeclampsia 5
  • PTSD: 23% endorse pregnancy-specific PTSD symptoms 5

Critical Pitfalls to Avoid

  1. Delaying transport for BP control: Initiate antihypertensives en route, not on scene
  2. Aggressive fluid resuscitation: Causes pulmonary edema—maintain KVO only
  3. Lowering BP too rapidly: Target 140-150/90-100 mmHg to maintain placental perfusion
  4. Assuming "normal" BP is reassuring: BP may be normal between measurements in early preeclampsia
  5. Dismissing headache as "pregnancy-related": Severe headache after 20 weeks is preeclampsia until proven otherwise
  6. Forgetting magnesium sulfate: Essential seizure prophylaxis in severe preeclampsia
  7. Using contraindicated medications: No ACE inhibitors, ARBs, or atenolol in pregnancy
  8. Positioning supine: Always maintain left lateral tilt to prevent supine hypotensive syndrome
  9. Inadequate seizure precautions: Have suction and airway equipment immediately available
  10. Underestimating disease progression: Preeclampsia can deteriorate rapidly—high index of suspicion required

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.